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Background: Crizotinib inhibits ALK, MET and ROS1 tyrosine kinases but the develop-
ment of resistance to monotherapy is an issue. The anti-angiogenic properties of pazopanib 
could overcome crizotinib drug resistance. Additionally, the anti-angiogenic properties of 
crizotinib could augment the clinical efficacy of pazopanib.
Methods: We evaluated the safety and responses in patients with advanced solid tumors 
treated with crizotinib and pazopanib.
Results: Eighty-two patients (median age 53 years, range 18–78 years) were enrolled. The 
median number of prior systemic therapies was 3 (range, 0–8). We were able to dose escalate 
to dose level 8 (crizotinib 250 mg twice daily and pazopanib 800 mg daily) with no MTD 
identified. Grade 3 or 4 toxicities were seen in 32% of patients with the highest prevalence 
being fatigue (n=9, 11%), diarrhea (n=6, 7%), vomiting (n=3, 4%), anemia (n=2, 2%) and 
ALT increased (n=2, 2%). Of the 82 patients, 61 (74%) had measurable disease by 
RECISTv1.1 and reached first restaging (6 weeks). Partial response (PR) was observed in 
6/61 (10%) patients, and stable disease (SD) lasting ≥6 months was observed in 10/61 
patients (16%) (total = 16/61 (26%) of patients with SD ≥6 months/PR).
Conclusion: Dose level 6 (crizotinib 200 mg twice daily and pazopanib 600 mg daily) was 
the most tolerable dosing of the combination and can be used in future studies. We also 
observed moderate clinical activity in patients with advanced solid tumors that had received 
numerous prior therapies.
Keywords: crizotinib, pazopanib, VEGF, ALK/ROS1, MET
Introduction
Crizotinib is a potent first-generation inhibitor of the anaplastic lymphoma kinase (ALK), 
MET (c-MET), and c-ROS oncogene 1 (ROS1) receptor tyrosine kinases and is approved 
for the treatment of patients with non-small cell lung cancer (NSCLC), who have tested 
positive for either ALK or ROS1 rearrangement.1–4 Crizotinib approval as a first-line 
therapy for patients with previously untreated ALK-positive NSCLC was based on its 
superior objective response rate and improved progression free survival compared to 
standard first-line doublet chemotherapy.5 Additionally, in preclinical studies, crizotinib 
(previously known as PF-02341066) was found to inhibit tumor cell growth in other solid 
tumors cell lines and xenograft models, including prostate, squamous head and neck 
cancer, osteosarcoma, ovarian cancer and renal cancer.6–10
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Studies have shown that the majority of patients treated 
with crizotinib initially have tumors that show a robust 
response, but eventually and almost invariably, develop 
drug-resistance.11,12 To address this, next-generation 
ALK inhibitors have been developed and are approved 
for first, second, and third line ALK positive NSCLC. 
However, ultimate recurrence through this sequence of 
ALK inhibitors occurs over time. Thus, there is an interest 
in developing combination therapies for ALK inhibitors 
with other therapeutic agents to increase the duration of 
response and sustain clinical benefit. Multiple bypass 
molecular pathways are ascribed to ALK resistance.13 
The angiogenesis pathway, for example, is considered as 
one of the essential requirements for disease progression in 
various solid tumors.14 Blocking the angiogenesis pathway 
has been shown to be effective in multiple solid tumors 
inclusive of thyroid, lung, ovarian and other cancers.15 The 
combination of existing chemotherapy with anti-angiogen-
esis drugs has been tested in multiple cancer types;16,17 for 
example, bevacizumab combined with pemetrexed18,19 
and sunitinib in combination with pemetrexed.20 Dual 
inhibition of cMET and VEGF has also been shown to 
be more effective than single pathway inhibition alone in 
pre-clinical models.21 Interestingly, crizotinib is also 
shown to have some anti-angiogenic activity in addition 
to its anti-proliferative effects.22
Pazopanib is a multi-kinase, angiogenesis inhibitor 
known to block VEGFR, PDGFRα, PDGFRβ and C-KIT 
and is approved for the treatment of patients with renal cell 
cancer23 and advanced soft tissue sarcoma (STS) who have 
received prior chemotherapy.24 We hypothesized that the 
combination of crizotinib with pazopanib would augment 
the clinical efficacy of pazopanib through dual inhibition of 
angiogenesis pathways in patients and additionally that in 
patients whose tumors harbored ALK, MET or ROS1 deleter-
ious aberrations, pazopanib would augment crizotinib ther-
apy and help overcome drug resistance. Here we report our 
experience treating patients with advanced malignancies 
with this combination therapy.
Patients and Methodology
Study Design and Dosing
This is a single institution, open-label, phase I dose-esca-
lation study in patients with advanced malignancies (NCT 
01548144). This trial was open to all patients with 
advanced or metastatic cancer refractory to standard ther-
apy, relapsed after standard therapy, or who had no 
standard therapy available that could improve survival by 
at least three months.
Treatment was administered on an outpatient basis at 
the University of Texas, MD Anderson Cancer Center. The 
cycle of therapy was 21 days. No investigational, commer-
cial agents or therapies other than those described here 
could be administered with the intent to treat the patient’s 
malignancy. Pazopanib was given orally once daily, while 
the crizotinib schedule varied according to dose levels. 
This single institution study protocol was approved by 
the Institutional Review Board at the University of 
Texas, MD Anderson Cancer Center and was conducted 
in accordance with the Declaration of Helsinki, Good 
Clinical Practice, and all local and federal regulatory 
guidelines. All patients signed informed consent prior to 
enrolling onto the study.
The protocol followed a standard 3+3 design.25 If one 
patient in a cohort experienced a dose-limiting toxicity (DLT) 
during the first cycle, three additional patients were enrolled 
and treated at that dose level. If at any time more than 33% of 
patients in a cohort experienced a DLT, that cohort was closed 
to additional patients. Adverse events (AE) were graded, based 
on the Common Terminology Criteria for Adverse Events, 
version 4.0 (CTCAEv4.0). DLTs were defined as any grade 3 
or 4 non-hematologic toxicity related to any of the study drugs 
(except nausea and vomiting responsive to appropriate medical 
interventions, correctable electrolyte imbalances or alopecia); 
any grade 4 hematologic toxicity lasting 3 weeks or longer 
despite supportive care; any grade 4 nausea or vomiting > 5 
days despite maximum anti-nausea regimens; any other grade 
3 non-hematologic toxicity including symptoms/signs of vas-
cular leak or cytokine release syndrome; any severe or life- 
threatening complication/abnormality not defined in the 
CTCAEv4.0 that was attributable to the therapy. The max-
imum tolerated dose (MTD) was defined by DLTs that 
occurred in the first cycle (three weeks). If a response was 
observed in a particular tumor type with the study drug combi-
nation, expanded enrollment was permitted for up to a total of 
14 patients with that tumor type at the highest dose level 
deemed safe at the time of patient enrollment. Furthermore, 
expansion group also included patients with activating 
abnormalities for which there is evidence that crizotinib has 
antitumor activity including ALK translocations, amplification 
and mutations, MET amplification and mutations and ROS1 
rearrangements (e.g. FIG1-ROS1 translocation).
All enrolled participants, including patients in the 
expansion group, were considered in the DLT analysis. 
For the purpose of dose expansion, a tumor response was 
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defined as one or more of the following: 1) stable disease 
for more than or equal to four months (SD ≥ 4 months), 
or 2) decrease in the sum of target lesions by more than or 
equal to 20% by Response Evaluation Criteria in Solid 
Tumors (RECIST criteria v1.1).
Eligibility Criteria
Key inclusion criteria included patients with any advanced 
cancer, either refractory to standard therapy or for which no 
effective standard therapy exists; evaluable or measurable 
disease by RECISTv1.1 criterion; Eastern Cooperative 
Oncology Group (ECOG) status ≤2; adequate organ func-
tions with absolute neutrophils > 1000 cells/uL, platelets ≥ 
75,000/uL, total bilirubin ≤ 2 x ULN (upper limit of normal), 
alanine transaminase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver 
metastases present) and serum creatinine < 2 x ULN; and 
women of child-bearing potential and men must agree to use 
adequate contraception. Key exclusion criteria were patient 
receiving any concurrent chemotherapy other than study 
drugs; any uncontrolled inter-current illness including, but 
not limited to, ongoing or active infection requiring intrave-
nous antibiotics; any symptomatic congestive heart failure; 
any history of stroke or transient ischemic attack within 6 
months prior to study enrollment; any history of abdominal 
fistula, gastrointestinal perforation, or intra-abdominal 
abscess within 6 months prior to study enrollment and 
patients with proteinuria ≥ 2+ by urine test.
Assessment of Tumor Response
Tumor measurements were performed on patients with mea-
surable disease at baseline and every two cycles (6 weeks) 
thereafter. Measurable target lesions were evaluated for 
response using RECIST v1.1.26,27 RECIST v1.1 defines par-
tial response (PR) as at least 30% reduction in the sum of 
target lesions compared to baseline. Progressive disease (PD) 
is defined as an increase in disease of at least 20% compared 
to the smallest sum recorded (nadir) with an increase of at 
least 5 mm in absolute value. Stable disease (SD) is defined 
as neither PR, nor PD. For the purpose of this report, pro-
longed stable disease (SD) was defined as lasting ≥ 6 months.
Results
Patient Characteristics
Eighty-two patients with advanced or metastatic solid 
malignancies were enrolled between April 2012 and 
December 2017. Out of 82 patients, 49 patients partici-
pated in dose-escalation and the remaining 33 patients 
participated in dose-expansion. Demographics, clinical 
characteristics and patient distribution are summarized 
in Table 1. The median age of patients was 53 years 
(range, 18–78 years). The median number of prior sys-
temic therapies was 3 (range, 0–8). Before enrollment 
onto the trial, one NSCLC patient with an undocumen-
ted/unknown history of an ALK translocation had 
received prior crizotinib for 9 months while 16 patients 
including sarcoma (6) and renal cancer (10) had 
received prior pazopanib. The median duration of prior 
pazopanib therapy was 9.3 months (range, 1.4 to 38.5 
months). Out of 82 patients, 34 patients had other prior 
anti-angiogenic therapy, either as single agent or in 
combination. These anti-angiogenic therapies mainly 
consisted of bevacizumab (23), sunitinib (12), and/or 
Table 1 Baseline Demographics and Clinical Characteristics
Characteristics Total Patients
N=82



















Salivary Gland 3 (4%)
Uveal Melanoma 3 (4%)
Thyroid 3 (4%)
Other tumor types** 34(41%)
Notes: **Other tumor types includes (N): cholangiocarcinoma (2), sarcoma (14), 
hepatocellular carcinoma (2), non-small cell lung cancer (2), urothelial carcinoma 
(2), adrenocortical carcinoma (1), appendiceal carcinoma (1), squamous cell carci-
noma of tonsil (1), granular cell tumor of the foot (1), melanoma (1), mesothelioma 
(1), gastroesophageal junction cancer (2), nasopharyngeal carcinoma (1), pancreatic 
cancer (1), pilocytic astrocytoma (1), and squamous cell carcinoma of vulva (1). 
Abbreviations: N, number of patients; ECOG, Eastern Cooperative Oncology Group.
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axitinib (6). The most common cancer type was renal 
cell carcinoma (n=16) followed by ovarian cancer 
(n=10). All patients had experienced disease progression 
during their prior therapy. The median number of cycles 
completed for all patients was 4 (range, 1–69). Fifty 
patients (61%) received more than 2 cycles. For patients 
with SD ≥ 6 months or better, the median number of 
cycles completed was 10 (range, 8–69). A total of 33 
patients were recruited into the expansion cohort 
designed to further evaluate toxicity and antitumor 
activity in select tumor types. The following tumor 
types were enrolled: renal cancer (n=11), ovarian cancer 
(n=7), colorectal cancer (n=3), soft tissue sarcomas 
(n=5), salivary gland tumors (n=2), breast cancer (n=1) 
and additional tumors with either ALK or MET aberra-
tions (n=4).
Toxicity Assessment
Patients were enrolled in accordance with the planned 3 
+3 study design until dose level 4 (Table 2, Table 3), at 
which point an expansion cohort for response (as 
described in the Methodology section) was initiated. 
Dose escalation for the remaining four levels continued 
in accordance with the original dose escalation plan. 
Dose level 8 (crizotinib 250 mg twice daily and pazo-
panib 800 mg daily) was reached and no MTD was 
obtained as we were able to reach the highest FDA- 
approved doses of both drugs.
Seventy-seven patients (94%) experienced at least one 
adverse event that was possibly drug related. These 
events were mostly grade 1 or 2 and reversible. In fact, 
56 patients (68%) experienced no treatment-related 















1 250 QOD 200 4 4 0 Fatigue (2) 0/3
2 200 daily 200 4 4 0 – 1/3
3 200 daily 400 5 5 0 – 1/3
4 250 daily 400 10 7 3 Thrombocytopenia (2), 
perforation of colon (1)
3/8
5 250 daily 600 9 7 2 Subdural hemorrhage (1), 
vomiting (1), diarrhea (1), anemia 
(1), ALT increase (1), AST 
increase (1), shortness of breath 
(1)
3/8
6 200 BID 600 33 5 28 FatigueΔ (4), fever (1), hematuria 
(1), diarrheaΔ (2), hyponatremiaΔ 
(1), ALT increased (1), ALP 
increased (1), anemia (1), 
neutropenia (1), nausea (1), 
vomiting (1), dizziness (1), 
abdominal painΔ (1)
6/26
7 200 BID 800 9 9 0 DiarrheaΔ (2), esophagitis (1), 
fatigueΔ (2), rash (1), vomiting (1), 
fatigue (2)
1/5
8 250 BID 800 8 8 0 Dyspnea (1), anorexia (1), fatigue 
(1), diarrhea (1),
1/5
Notes: *Adverse events deemed at least possibly related to treatment were graded based on the Common Terminology Criteria for Adverse Events, version 4.0 
(CTCAEv4.0). #Patients were evaluable for response if they had at least one post-baseline scan. ΔEvent was defined as a dose-limiting toxicity. 
Abbreviations: N, number of patients; QOD, every other day; BID, twice a day; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.
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toxicity greater than grade 2. The most common grade 3 
or 4 toxicities were as follows: fatigue (n=9, 11%), diar-
rhea (n=6, 7%), vomiting (n=3, 4%), anemia (n=2, 2%) 
and ALT increased (n=2, 2%) (Table 3). Among this 
subset of patients (≥ grade 3 AEs), we observed 3 DLTs 
(Table 2). At dose level 7, we observed 2 DLTs out of 9 
patients enrolled (<33%). One patient had grade 3 fatigue 
while another patient had concurrent grade 3 fatigue and 
grade 3 diarrhea. The first patient recovered after a brief 
interruption in dosing and subsequent dose-reduction. He 
went on to complete 6 cycles of treatment before being 
taken off the study for disease progression. The second 
patient was taken off the study after only 4 days of dosing 
due to increased fatigue and poor tolerance to therapy. At 
dose level 8, one patient had grade 4 dyspnea outside the 
DLT period. The therapy was discontinued for this 
patient to remediate toxicity. Considering two occur-
rences of DLTs at dose level 7 and 1 patient’s disconti-
nuation at dose level 8 due to toxicity, it was decided to 
continue all further expansion enrollment at dose level 6. 
During expansion, an additional patient at dose level 6 
experienced DLT, with concurrent grade 3 hyponatremia, 
grade 3 fatigue and grade 3 diarrhea. In total, we 
observed DLT in 1 of 33 (3%) patients treated at dose 
level 6 including our expansion cohort patients. During 
this study, seven patients died while active in this trial, 
but none of these deaths were attributed to the study 
drugs. All deaths were due to disease progression except 
in one patient (NSCLC) at dose level 1 who died of post- 
obstructive pneumonia.
Table 3 Adverse Events at Any Dose Level
Adverse Events Dosing Level Total Events
1 2 3 4 5 6 7 8
Count Count Count Count Count Count Count Count
Fatigue Grade ≤2 1 2 3 6 5 23 6 4 50
Grade ≥ 3 2 0 0 0 0 4 2 1 9
Nausea Grade ≤2 0 4 2 8 2 19 6 6 47
Grade ≥ 3 0 0 0 0 0 1 0 0 1
Diarrhea Grade ≤2 1 1 2 3 2 15 2 0 26
Grade ≥ 3 0 0 0 0 1 2 2 1 6
Vomiting Grade ≤2 0 2 2 2 2 13 1 4 26
Grade ≥ 3 0 0 0 0 1 1 1 0 3
Anorexia Grade ≤2 2 0 1 2 1 9 4 6 25
Grade ≥ 3 0 0 0 0 0 0 0 1 1
ALT increased Grade ≤2 1 1 2 1 1 9 1 0 16
Grade ≥ 3 0 0 0 0 1 1 0 0 2
AST increased Grade ≤2 1 1 2 2 2 11 2 0 21
Grade ≥ 3 0 0 0 0 1 0 0 0 1
Anemia Grade ≤2 2 1 0 1 3 6 1 2 16
Grade ≥ 3 0 0 0 0 1 1 0 0 2
Other AEs Grade ≤2 5 1 8 7 13 76 21 27 158
Grade ≥ 3 0 0 0 3 2 7 2 1 15*
Notes: *Other AEs Grade ≥3 (number of patients in parenthesis) includes thrombocytopenia (2), abdominal pain (1), increased alkaline phosphatase (1), dyspnea (1), fever 
(1), hematuria (1), esophagitis (1), dizziness (1), hyponatremia (1), neutropenia (1), colon perforation (1), rash (1), subdural hemorrhage (1), shortness of breath (1).
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Overall, 16/82 (20%) patients had dose reduction of 
either crizotinib (n=3) or pazopanib (n=9) or both (n=4) 
during their course of treatment. Of these 16 patients, nine 
patients (56%) were dose-reduced for pazopanib at dose 
level 6 for various toxicities, including fatigue (5), 
increased transaminases (2), diarrhea (1) and nausea (1). 
Three patient additionally had crizotinib dose reduced 
from 200mg BID to 250mg daily for fatigue (1), diarrhea 
(1) and nausea (1). At dose level 7, two patients had 
pazopanib dose reduced from 800 mg daily to either 
600 mg daily or 400 mg daily for diarrhea (1) or fatigue 
(1) while one patient had crizotinib dose reduced from 
250 mg BID to 250 mg daily for grade 3 rash. Another 
patient had both pazopanib dose reduction to 400mg daily 
and crizotinib dose reduction to 250mg daily for grade 2 
elevated bilirubin. At dose level 8, two patients had crizo-
tinib dose reduced for bradycardia (1) and esophagitis (1) 
while one patient had pazopanib dose reduced for fatigue. 
Most of the dose reductions helped patients continue on 
the trial for at least one more cycle of treatment.
Antitumor Activity
Of 82 total patients on the trial, 61/82 (74%) patients had 
disease that was measurable by RECISTv1.1 and reached 
first restaging (6 weeks); 1/82 (1%) patient had a non- 
measurable disease at baseline and was excluded from 
image analysis for tumor efficacy; and 20/82 (24%) 
patients were taken off the study before first restaging 
for various reasons including drug-related toxicities 
(n=2), clinical disease progression (n=11), death (n=4) or 
voluntary withdrawal from the clinical trial (n=3). Figure 1 
is a waterfall plot depicting the best response of the 61 
response-evaluable patients. Partial response (PR) was 
observed in 6/61 (10%) patients and stable disease (SD) 
lasting ≥ 6 months was observed in 10/61 patients (16%) 
(total = 16/61 (26%) of patients with SD ≥6 months/PR). 
Supplementary Figure 1 shows swimmer plots depicting 
best RECISTv1.1 response and duration of time during 
treatment.
Tumor types of patients with best response of PR 
include ovarian cancer (1), colorectal cancer (1), sarcoma 
(2), clear cell renal cancer (1) and granular cell tumor of 
the foot (1). In total, 3 out of 9 (33%) evaluable patients 
with ovarian cancer and 3 out of 14 (21%) evaluable 
patients with renal cancer had SD≥6 months/PR. Out of 
9 patients enrolled in this trial with either MET or ALK 
aberrations, one patient with colon cancer and ALK p. 
R1209Q mutation had a best response of PR (−33%) on 
dose level 6 and one patient with salivary gland tumor and 
MET p.N375S mutation had a best response of SD ≥6 
months on dose level 5. Among other patients with PR 
as best response to therapy, we had a clear cell renal 
cancer patient (−32%, PR) with a Kinase Insert Domain 
Receptor (KDR) p.C482R mutation previously treated with 
Figure 1 Waterfall plot depicting best RECISTv1.1 response. Individual patients are represented by vertical bars on the X-axis and best RECISTv1.1 response is depicted as 
percentage on the Y-axis. Sixty one of 82 patients had at least one post-baseline scan and were evaluable for response. Two patients were marked as progressive disease even 
though their percentage of tumor increase was less than 20% because of new lesions (*). Dotted lines show 20% increase and 30% decrease in tumor size by RECISTv1.1.
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multiple lines of therapy including pazopanib monother-
apy for a year (best response on monotherapy was SD). 
After progression on pazopanib monotherapy, she com-
pleted 36 weeks on our crizotinib and pazopanib combina-
tion study before being taken off the trial because of a new 
lesion in the spine.
Interestingly, patients with fusion transcripts also 
showed good response including patients (N=1 for each 
fusion) with Ewing Sarcoma Breakpoint 1 (EWSR1)- 
CAMP Responsive Element Binding Protein (CREB1) 
(−60%, PR), Dynactin Subunit 1 (DCTN1)-ALK (−32%, 
PR) and EWSR1-CREB3L1 (4%, SD). The patient with an 
EWSR1-CREB1 fusion who had clear cell sarcoma of the 
bowel completed 69 cycles at dose level 5 before with-
drawing consent to participate in another clinical study 
closer to home. The patient with a DCTN1-ALK gene 
fusion (detected by next-generation sequencing genomic 
testing and confirmed by diffuse ALK expression by 
immunohistochemistry) who had a myxoid neoplasm of 
the uterus completed 41 cycles at dose level 6. Finally, the 
patient with EWSR1-CREB3L1 fusion who had 
a sclerosing epithelioid fibrosarcoma (SEF) of the abdom-
inal wall completed 26 cycles of treatment at dose level 8.
Discussion
This is the first report of combining crizotinib with pazo-
panib and results demonstrate that this combination has 
a tolerable safety profile, with mild to moderate adverse 
events in patients with advanced solid tumors. No new or 
unexpected adverse events were observed during this 
study. Despite having eight dose levels, we were unable 
to define the MTD of crizotinib plus pazopanib in combi-
nation as the Food and Drug Administration (FDA) 
approved doses for both drugs were administered without 
any significant DLTs. The toxicity evaluation revealed that 
94% (77/82) of patients had at least one adverse event that 
was possibly drug-related but approximately two-thirds of 
these patients (68%) had toxicity of grade 2 or less. The 
most common grade 3 and 4 toxicities included: fatigue 
(11%), diarrhea (7%), vomiting (4%), anemia (2%) and 
increased ALT (2%). The most common (occurring in 
more than 30% of all patients) non-hematologic adverse 
events, irrespective of grade, were fatigue (71%), nausea 
(58%), diarrhea (39%), vomiting (35%) and anorexia 
(30%) and for hematological toxicities, irrespective of 
grade, were anemia (22%) and leukopenia (13%).
Most of the AEs experienced in our study are consis-
tent with prior reported AEs with either crizotinib and/or 
pazopanib monotherapy. Clinical trials with crizotinib 
monotherapy in patients with advanced NSCLC that was 
ALK-positive or ROS-positive reported visual effects, 
nausea, diarrhea, vomiting, constipation, edema, elevated 
transaminases, and fatigue as the common adverse events 
(in >25% of patients) irrespective of their grades.5,28–31 
Visual disorders of grade 1 or 2 severity were the most 
frequently observed AEs with crizotinib monotherapy and 
were captured by using a patient-reported questionnaire. 
Unfortunately, our study lacked this type of assessment 
and may be a reason for the lack of visual changes being 
reported in any of our treated patients.
More serious toxicities associated with crizotinib 
monotherapy include hepatotoxicity, interstitial lung dis-
ease/pneumonitis, and QT-interval prolongation.32 In fact, 
ALT increase (17%) was the most common grade 3–4 
toxicity observed in these prior studies. In our study, 
hepatotoxicity was also observed, albeit much milder in 
comparison to these previous reports as 26% of patients in 
our study experienced grade 1–2 increased AST and 20% 
patients experienced grade 1–2 increased ALT. Further, 
only 2% of all enrolled patients in our study experienced 
grade ≥ 3 increase in ALT.
A previous Phase III randomized study (VEG105192) 
with pazopanib as single agent in patients with advanced 
renal cell carcinoma (RCC) reported diarrhea (52%), 
increased AST (53%), increased ALT (53%), hypertension 
(40%), hair color changes (38%), nausea (26%), vomiting 
(21%) and fatigue (19%) as the most common AEs of any 
grade.23 A phase III study (COMPARZ) in RCC evaluated 
pazopanib versus sunitinib and reported diarrhea (63%), 
increased AST (61%), increased ALT (60%), fatigue 
(55%), hypertension (46%), nausea (45%), hair depigmen-
tation (30%), hand-foot syndrome (29%), and vomiting 
(28%), irrespective of severity of grade. In our study, we 
observed less hepatotoxicity and diarrhea compared to the 
COMPARZ and VEG105192 studies but more fatigue 
which occurred in 71% of the patients.23,33
In terms of efficacy, in 61 response evaluable patients, 
we had 6 PRs (10%) and 10 patients (16%) with SD ≥ 6 
months (SD ≥ 6 months/PR of 26%). Three patients (3/16; 
19%) with SD ≥ 6 months or PR, had deleterious ALK or 
MET aberrations (Table 4). Of these 3 patients, none had 
received prior ALK or ROS1 inhibitors and only 1 patient 
had received a prior MET inhibitor. FDA accelerated 
approval of crizotinib for advanced NSCLC (ALK posi-
tive) was based on findings from two phase I and II 
trials.4,34,35 In a phase I study (PROFILE 1001) with 
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ALK-positive NSCLC patients, Camidge et al29 reported 
a 60.8% objective response rate (ORR) among 143 
response-evaluable patients. Of these 143 patients, 3 
patients had a CR and 84 patients had a PR and the clinical 
benefit rate (CR+PR+SD) at weeks 8 and 16 was 82.5% 
and 70.6%, respectively.29 Updated results from a Phase II 
study with crizotinib (PROFILE 1005) demonstrated 54% 
ORR among 908 response-evaluable patients with central 
ALK-testing with 11 (1%) patients having achieved CR 
and 480 (53%) patients having achieved PR.28 Six patients 
(6/16; 38%) with SD ≥ 6 months or PR, had wild type 
ALK, MET and ROS1 on molecular testing (Table 4). Of 
these 6 patients, 3 had had prior antiangiogenics (prior 
bevacizumab n=2; prior axitinib n=1). A phase II study 
with pazopanib in patients with advanced metastatic RCC 
showed a response rate (CR+PR) of 35% with 1.3% CR, 
33.3% PR and 44.9% SD (>8 weeks).36 Reasons for the 
differences in response between our study and these stu-
dies are multifactorial, including: 1) heterogeneous tumor 
types enrolled in our study; 2) heavily pre-treated patients 
with a median of 3 prior systemic therapies in our study; 
and, 3) lack of genomic selection for enrollment into our 
study.
Interestingly, a patient with DCTN1-ALK gene fusion 
showed a partial response (−32%) to therapy.37 DCTN1- 
ALK fusions have been observed recurrently in multiple 
tumor types including spitz tumors, lung cancer and 
inflammatory myofibroblastic tumors.38–40 Shimada et al41 
has characterized the DCTN1-ALK fusion protein and 
showed that it is a potential oncogene that can be used 
as a target for ALK tyrosine kinase inhibitors including 
crizotinib and alectinib. The gene fusion event confers 
constitutive activation of ALK and treatment with crizoti-
nib inhibited constitutive phosphorylation of ALK and 
activation of downstream PI3K and MAPK signaling 
cascades.38 Recently, Michels et al42 has demonstrated 
that an ALK p.G1269A mutation was detected in 
a patient with DCTN1-ALK fusion who developed 
acquired resistance to crizotinib. Unfortunately, we were 
unable to obtain a repeat biopsy in our patient and there-
fore we could not confirm if any new mutations in ALK 
could have possibly contributed to the emergence of ther-
apeutic resistance.
We also observed that a patient with EWSR1-CREB1 
fusion favorably responded to crizotinib and pazopanib 
combination treatment. Our clear cell sarcoma patient 
was negative for EWSR1-activating transcription factor-1 
(ATF1) fusion transcripts and was able to complete 69 
cycles (>4 years) on dose level 5 with a best response of 
PR (−60%). Ultimately, the patient withdrew consent from 
the study in order to pursue treatment closer to home.43 
Most EWSR1 fusions involve the 5ʹ portion of EWSR1 
which acts as an activator of the DNA binding region of its 
fusion partner targeting the fusion of specific promoters. 
CREB1 binds cAMP response elements within target 
genes to upregulate gene expression. EWSR1-ATF1 fusion 
protein is known to activate the melanocyte master tran-
scription factor (MITF) which further activates the MET 
gene.44 It is however not known if all EWSR1-fusion 
proteins are capable of activating cMET expression. 
Nevertheless, it is hypothesized that these fusions sensitize 
tumor cells to cMET and/or ALK inhibitors.
Similarly, another patient with sclerosing epithelioid 
fibrosarcoma (SEF) and EWSR1-CREB3L1 fusion com-
pleted 26 cycles of treatment with a best response of SD. 
SEFs are considered rare but aggressive tumors arising 
from deep tissues and characterized by EWSR1- 
CREB3L1 translocation.45 Unfortunately, there are no 
standardized treatment regimens for SEFs and these 
tumors are quite challenging to manage. The unusual 
response of SEFs with EWSR1-CREB3L1 fusion to com-
bination therapy with crizotinib and pazopanib has not 
been reported. Intriguingly, a recent phase II trial (90,101 
“CREATE”) evaluated the efficacy and safety of crizotinib 
in patients with advanced clear cell sarcoma (CCSA) with 
EWSR1/ATF1 fusions and showed an ORR of only 3.8%,46 
and adds to speculation that fusion partner genes of 
EWSR1 may be an important determinant of clinical effi-
cacy to crizotinib. This however needs further testing.
Apart from the interesting gene-fusion patients dis-
cussed, we observed that a patient with KDR p.C482R 
mutation achieved PR with our combination therapy. 
KDR is also known as vascular endothelial growth fac-
tor receptor-2 (VEGFR-2). The p.C482R mutation is 
a gain-of-function mutation leading to constitutive 
dimerization and activation of VEGFR-2 and this var-
iant of KDR has been shown to highly correlate with 
serum-soluble VEGFR-2 level which is recognized as 
a pharmacodynamic response marker for pazopanib.47,48 
Our study lends support to the use of pazopanib either 
as a single agent or in combination with crizotinib for 
patients with KDR p.C482R mutation.
In conclusion, we determined that dose level 6 (cri-
zotinib 200 mg twice daily and pazopanib 600 mg daily) 
was the most tolerable dosing of this drug combination 
and could be used for future studies. We also 
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demonstrated moderate clinical activity in patients with 
advanced solid tumors that had received numerous prior 
therapies.
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